Efficacy and safety of the academic anti‐CD19 chimeric antigen receptor T‐cell product varnimcabtagene autoleucel for the treatment of relapsed/refractory follicular lymphoma
Authors:
Open Access
- 11 September 2025
- journal article
- Published by Wiley in HemaSphere
- Vol. 9 (9) , e70166
Abstract
We report the outcome of patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with varnimcabtagene autoleucel (var‐cel), an academic anti‐CD19 chimeric antigen receptor (CAR) T‐cell product. Patients were included in the CART19‐BE‐01 clinical trial and a compassionate use program. Twenty‐seven patients with FL were treated. Cytokine release syndrome (any grade) occurred in 55% of patients (4% Grade ≥3). Only 1 case (4%) of Grade 1 neurotoxicity was documented. The objective response rate was 100% at Day +100 (93% complete response rate), and the 3‐year duration of response was 78%. The 3‐year progression‐free survival and overall survival were 78% and 81%, respectively. All patients developed B‐cell aplasia, and the 3‐year incidence of B‐cell recovery was 17%. In conclusion, patients with R/R FL treated with var‐cel obtained excellent disease control, with prolonged CAR T‐cell survival and manageable toxicity. This trial was registered as NCT03144583.Keywords
This publication has 32 references indexed in Scilit:
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell LymphomaNew England Journal of Medicine, 2020
- Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical TrialFrontiers in Immunology, 2020
- Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2020
- Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapyBlood, 2019
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic InstitutionsMolecular Therapy - Methods & Clinical Development, 2019
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaNew England Journal of Medicine, 2019
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaNew England Journal of Medicine, 2017
- Acute Lymphoblastic Leukemia, Version 2.2015Journal of the National Comprehensive Cancer Network, 2015